Tier 3 — preclinical

Dietary betaine prevents obesity through gut microbiota-drived microRNA-378a family

Jingjing Du, Peiwen Zhang, Jiang Luo, Linyuan Shen, Shunhua Zhang, Hao Gu, Jin He, Linghui Wang, Xue Zhao, Mailing Gan, Liu Yang, Lili Niu, Ye Zhao, Qianzi Tang, Guoqing Tang, Dongmei Jiang, Yanzhi Jiang, Mingzhou Li, Anan Jiang, Long Jin, Jideng Ma, Surong Shuai, Lin Bai, Jinyong Wang, Bo Zeng, De Wu, Xuewei Li, Li Zhu
Gut microbes 2021 13(1):1

Bibliography

PubMed
PMID 33550882
PubMed Central
PMC7889173
DOI
10.1080/19490976.2020.1862612
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignExperimental animal and/or laboratory research
ModelHigh-fat-fed mice and microbiome experiments
SampleExperiment-specific biological replicates and model groups; see original methods
InterventionDietary betaine with microbiome and gene-pathway manipulations
DurationModel-specific dietary experiments
EndpointsObesity model; Microbiota; MicroRNA-378a

What the study showed, in plain terms

Published in 2021, this source examined preclinical aging, brain and metabolic mechanisms. Design: Experimental animal and/or laboratory research. Sample/model: Experiment-specific biological replicates and model groups; see original methods. The exposure or intervention was Dietary betaine with microbiome and gene-pathway manipulations. Follow-up or treatment period: Model-specific dietary experiments.

Betaine-associated metabolic effects depended partly on microbiota and were linked to a proposed microRNA-378a/YY1 pathway.

Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.

Continue with TMG Data Center

Continue with TMG for Weight Loss: Body-Fat Findings and Their Limits

Key findings

  • Betaine-associated metabolic effects depended partly on microbiota and were linked to a proposed microRNA-378a/YY1 pathway.
  • The recorded outcome domains were Obesity model; Microbiota; MicroRNA-378a.
  • The result applies to the tested exposure: Dietary betaine with microbiome and gene-pathway manipulations; Model-specific dietary experiments.

What this study can and cannot tell us

  • Experimental model evidence. The intervention, concentrations and outcomes do not establish an effective human supplement dose or a clinical treatment benefit.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 3
Systematic profiling reveals betaine as an exercise mimetic for geroprotection
Lingling Geng et al. · Cell · 2025
Tier 4
Betaine and aging: A narrative review of findings, possible mechanisms, research perspectives, and practical recommendations
Emilia Zawieja et al. · Ageing research reviews · 2025
Tier 4
Beneficial Effects of Betaine: A Comprehensive Review
Madan Kumar Arumugam et al. · Biology · 2021
Tier 4
Decoding Betaine: A Critical Analysis of Therapeutic Potential Compared with Marketing Hype-A Narrative Review
Grzegorz Nikrandt et al. · The Journal of nutrition · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology